Sunday, August 24, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Oppenheimer Analyst Maintains Positive Outlook on Clarivate with Revised Price Target

Elaine Mendonca by Elaine Mendonca
February 28, 2024
in Breaking News
0
SO stock news
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Oppenheimer analyst Owen Lau reaffirms his positive outlook on Clarivate (NYSE:CLVT) with an “Outperform” rating, but has revised the price target down to $10 from $11. This adjustment follows a previous update where the price target was increased from $10 to $11. Analysts have consistently rated Clarivate as “Outperform,” with price targets ranging from $10 to $15. Oppenheimer’s stock recommendations and price targets are highly regarded in the market, offering valuable guidance for investors.

CLVT Stock Plummets 17.45% in One Day: Investors Keep a Close Eye

On February 28, 2024, CLVT stock experienced a significant drop in its price performance. According to CNN Money, the stock closed at $7.38, which marked a decrease of $1.56 or 17.45% since the previous market close. Despite the negative performance during regular trading hours, there was a slight uptick in after-hours trading, with the stock rising $0.06. Investors and analysts will likely be monitoring the stock closely in the coming days to see if this drop in price is indicative of a larger trend or if it was a temporary fluctuation. It will be important to consider any relevant news or developments that may have contributed to the stock’s performance on this particular day.

CLVT Stock Performance Analysis: Mixed Results on February 28, 2024

On February 28, 2024, CLVT stock had mixed performances based on the financial data provided by CNN Money. The total revenue for the company stood at $2.63 billion for the past year, which remained flat compared to the previous year. Similarly, the total revenue for the fourth quarter was $683.70 million, also holding flat compared to the previous quarter.

The net income for CLVT showed contrasting trends. The net income for the past year was reported at -$911.20 million, which represented a 76.99% increase compared to the previous year. On the other hand, the net income for the fourth quarter was reported at -$843.90 million, indicating a significant decrease of 6960.98% compared to the previous quarter.

Earnings per share (EPS) for CLVT also displayed divergent trends. The EPS for the past year was reported at -$1.47, showing a 76.45% increase compared to the previous year. However, the EPS for the fourth quarter was reported at -$1.30, indicating a substantial decrease of 13141.84% compared to the previous quarter.

Overall, the financial performance of CLVT on February 28, 2024, showcased a mix of positive and negative indicators. Investors and analysts would need to closely monitor these financial metrics to assess the future prospects of CLVT stock.

Tags: CLVT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Investings on laptop and finances

Title Payoneer Global Remains Optimistic Despite Revenue Projection Dip

Empowering Beauty The Mission of Purple Boudoir

Pharmaceutical Markets and money

Mixed Results from PL9643 MELODY1 Phase 3 Clinical Trial for Dry Eye Disease

Recommended

Biotechnology Stock Exchange

Perions Groundbreaking Partnership with Wayio Expanding into Chinas Booming Digital Market

1 year ago
Mining technology

Webull Corporation to Go Public through SPAC Merger A GameChanging Move in Digital Investing

1 year ago

MindMeds MM120 Program Receives FDA Breakthrough Therapy Designation for Generalized Anxiety Disorder

1 year ago

Supernus Pharmaceuticals Wins Patent Infringement Case Secures Exclusivity for Trokendi XR

2 years ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN Apple AVGO BA C CELH COIN Coinbase COST CRWD DELL DIS DWAC Eli Lilly EQT GM GRFS IBM INTC JPM LLY META Micron MSFT NFLX NIO NVDA NVO PARA PLTR PLUG Robinhood SMCI Strategy TGT TSLA UNH VZ
No Result
View All Result

Highlights

Can Nike’s Jordan Brand Reclaim Its Air?

Rafael Holdings Shares Stage a Tentative Rebound After Steep Declines

B&G Foods Stock: Can Strategic Shifts Offset Persistent Headwinds?

Gilead Sciences: Navigating Setbacks and Strategic Investments

Fiserv Faces Class Action Lawsuit Over Business Practices

Oxford Lane Capital Shares Tumble on Unexpected Earnings Shortfall

Trending

Procter & Gamble Stock
Stocks

Insider Selling Spree Raises Questions at Procter & Gamble

by Dieter Jaworski
August 24, 2025
0

A significant wave of insider selling activity at Procter & Gamble is drawing investor scrutiny. Corporate leaders...

Oracle Stock

Oracle’s AI Ambition: Market Optimism Meets Investor Skepticism

August 24, 2025
Salesforce Stock

Activist Investor Targets Salesforce Amid Market Challenges

August 24, 2025
Nike Stock

Can Nike’s Jordan Brand Reclaim Its Air?

August 24, 2025
Rafael Stock

Rafael Holdings Shares Stage a Tentative Rebound After Steep Declines

August 24, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Insider Selling Spree Raises Questions at Procter & Gamble August 24, 2025
  • Oracle’s AI Ambition: Market Optimism Meets Investor Skepticism August 24, 2025
  • Activist Investor Targets Salesforce Amid Market Challenges August 24, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Cryptocurrency
  • ETF
  • Index
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com